Objectives: The objective of the present study was to evaluate the effectiveness and safety of
adalimumab (ADA) in children with Crohn disease (CD) who experienced infliximab (IFX) …

Introduction Children and adolescents with Crohn's disease present unique challenges due
to extensive disease at diagnosis and the effect of bowel inflammation on growth. Historical …

Background In a nationwide cohort, we aimed to compare the durability of infliximab and
adalimumab as first biologic treatment in children with Crohn's disease (CD), stratified as …

The introduction of biological agents with strong anti-inflammatory action, such as antitumor
necrosis factor (TNF) agents, has greatly contributed to changes in inflammatory bowel …

Background and aims: Patients with Crohn's disease (CD) may need anti-inflammatory
drugs for decades. Anti-TNF-α agents have good efficacy and adverse events similar to …

The immunomodulators (6-mercaptopurine, azathioprine and methotrexate) and biologics
(infliximab, adalimumab, certolizumab and natalizumab) are medications essential in the …

Incidence of inflammatory bowel diseases (IBDs), including Crohn's disease (CD) and
ulcerative colitis (UC), is increasing worldwide. Children with IBDs have a dysfunctional …

AIM: To study whether adalimumab (ADA) was associated with improvement in growth, bone
mineral density (BMD) and bone metabolism. METHODS: In children with Crohn's disease …

Background Prior studies evaluating the relationship between tumor necrosis factor–alpha
inhibitors (TNFI) and infection were conducted in adults and had conflicting findings. We …

Psoriasis is a chronic inflammatory disease that is not un-common in children and
adolescents. While exact prevalence rates of pediatric psoriasis have not been determined …